profit from every $100 of sales.
$0$100
USANA Health Sciences
$13.24+4.01% today
-31.6% in 1 year
1-year low $12.731-year high $23.24
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $22.74 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What USANA Health Sciences sold, what it kept, and what it did with the cash.
Sales went from $999 million in 2022 to $925 million in 2025, with $10.8 million of profit last year.
SalesProfit
USANA Health Sciences handed back more cash to shareholders than it generated last year.
Buybacks $28M
Free cash flow 2025$9M
Bought back its own shares$28M
Paid as dividends–
Cash vs. debt$158M vs. $20M
USANA Health Sciences vs. similar companies
USANA Health Sciences grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| USANA Health Sciences | 22.7× · Fair price | ||
 Nestlé | 25.0× · Fair price | ||
 Danone | 24.6× · Fair price | ||
 JBS | 19.8× · Fair price | ||
 Foshan Haitian Flavouring and Food | 29.0× · Fair price |
AI analysis
An AI analyst reads USANA Health Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 999 | 921 | 855 | 925 | |
| 805 | 744 | 693 | 724 | |
| 108 | 93 | 66 | 51 | |
| 130 | 123 | 99 | 82 | |
| 69 | 64 | 42 | 11 | |
| 3.59 | 3.30 | 2.19 | 0.58 | |
| 80.6% | 80.8% | 81.1% | 78.3% | |
| 10.8% | 10.1% | 7.8% | 5.5% | |
| 6.9% | 6.9% | 4.9% | 1.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 597 | 633 | 748 | 743 |
| Cash | 288 | 330 | 182 | 158 |
| Total debt | 7 | 8 | 29 | 20 |
| Total liabilities | 162 | 136 | 162 | 157 |
| 434 | 497 | 532 | 533 | |
| 19 | 19 | 19 | 19 | |
| 19.5% | 16.1% | 10.8% | 6.1% | |
| 16.0% | 12.8% | 7.9% | 2.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 104 | 71 | 61 | 22 | |
| 10 | 14 | 10 | 14 | |
| 94 | 56 | 51 | 9 | |
| Dividends paid | – | – | – | – |
| 25 | 12 | 9 | 28 | |
| 13 | 15 | 15 | 14 |
Valuation
- 22.7×
- 6.8×
- –
- 0.6×
- 0.3×
- 28.7×
- 1.3×
- 3.5%
- 4.4%
- 0.0%
Profitability
- 78.3%
- 5.5%
- 1.2%
- 8.5%
- 1.8%
- 13.1%
- 1.7%
- 1.2%
- 7.9%
- –
Growth
- −2.5%
- −45.5%
- −83.3%
- –
- −2.0%
Financial health
- -1.9×
- 0.03
- 1.9%
- 73.1×
- 2.51
- 1.69
- 1.25
How it ranks in Consumer Staples
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 669
Bottom 26%of 672
Bottom 37%of 623
Bottom 10%of 671
Bottom 37%of 666
What analysts expect
- Average price target
- $35.00
- Range
- $35.00 – $35.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.61 | 0.44 | +38.6% |
| Feb 17, 2026 | 0.60 | 0.41 | +46.3% |
| Oct 21, 2025 | -0.15 | 0.25 | −160.0% |
| Jul 22, 2025 | 0.74 | 0.54 | +37.0% |
| Apr 22, 2025 | 0.73 | 0.70 | +4.3% |
| Feb 25, 2025 | 0.64 | 0.49 | +30.6% |
| Oct 22, 2024 | 0.56 | 0.49 | +14.3% |
| Jul 23, 2024 | 0.54 | 0.65 | −16.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
64Pass
Benjamin Graham
83Pass
Philip Fisher
49No pass
Peter Lynch
21No pass
Joel Greenblatt
48No pass
Charlie Munger
52No pass
Terry Smith
44No pass
Questions about USANA Health Sciences
Is USANA Health Sciences a good stock to buy?
A business with weak numbers at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the USANA Health Sciences AI analysis
What does USANA Health Sciences do?
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. It is in Packaged Foods.
Does USANA Health Sciences pay a dividend?
No. USANA Health Sciences does not pay a dividend at the moment; in 2025 it returned $27.5 million to shareholders by buying back its own shares.
Is USANA Health Sciences stock halal?
No. USANA Health Sciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 65% of its market value, at or above the 33% limit. How we check
How has USANA Health Sciences stock done over the past year?
Down 31.6% over the past twelve months, to $13.24. It traded between $12.73 and $23.24 and is 43.0% below its high.
Who are USANA Health Sciences's competitors?
The largest listed companies in the same industry are Nestlé, Danone, JBS and Foshan Haitian Flavouring and Food. The peers table on this page compares their profit, growth and price with USANA Health Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.